Neuroendocrine carcinoma of the jugular foramen.
We describe what might have been the first reported case of a neuroendocrine carcinoma of the jugular foramen. A 50-year-old woman presented with progressive left-sided sensorineural hearing loss, vertigo, pulsatile tinnitus, headaches, and ataxia. Magnetic resonance imaging revealed a 4-cm left-sided jugular foramen tumor. The patient underwent near-total resection of the tumor. Despite lower cranial nerve preservation, postoperative paralysis of cranial nerves IX and X occurred, and vocal fold medialization was performed 5 days later. The final pathologic diagnosis was neuroendocrine carcinoma. The patient was treated with concurrent chemotherapy and intensity-modulated radiation therapy. This article will discuss the pathologic features and the management of jugular foramen tumors, along with the differential diagnosis of these rare tumors.
Leonetti
John P
JP
Department of Otolaryngology-Head and Neck Surgery, Skull Base Surgery Center, Maywood, IL 60153, USA. jleonet@lumc.edu
Shirazi
Mobeen A
MA
Marzo
Sam
S
Anderson
Douglas
D
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001259:Ataxia / Q000209:etiology; D018278:Carcinoma, Neuroendocrine / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006261:Headache / Q000209:etiology; D006319:Hearing Loss, Sensorineural / Q000209:etiology; D006801:Humans; D007601:Jugular Veins; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant; D050397:Radiotherapy, Intensity-Modulated; D019292:Skull Base Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D014012:Tinnitus / Q000209:etiology; D014717:Vertigo / Q000209:etiology
D005047:Etoposide; D002945:Cisplatin